Table 2 Clinical factors associated with hepatocellular carcinoma
| Â | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
Parameters | HR | 95 % CI | P value | HR | 95 % CI | P value |
Age (years) | ||||||
  ≥ 60 (ref. <60) | 3.40 | 1.35–9.68 | 0.0085 |  |  | NS |
Male (ref. female) | 1.77 | 0.73–4.54 | 0.21 |  |  |  |
Body mass index (kg/m2) | ||||||
  ≥ 25.0 (ref. <25.0) | 1.28 | 0.46–4.53 | 0.65 |  |  |  |
Pre-treatment ALT (U/L) | ||||||
  ≥ 40 (ref. <40) | 3.12 | 1.04–13.46 | 0.042 |  |  | NS |
Post-treatment ALT (U/L) | ||||||
  ≥ 40 (ref. <40) | 7.01 | 2.69–21.76 | <0.0001 | 4.33 | 1.09–24.8 | 0.036 |
α-fetoprotein (ng/mL) | ||||||
  ≥ 10.0 (ref. <10.0) | 4.27 | 1.68–10.5 | 0.0030 |  |  | NS |
Fasting serum insulin (μU/mL) | ||||||
  ≥ 15.0 (ref. <15.0) | 3.99 | 1.61–9.78 | 0.0033 |  |  | NS |
HOMA-IR | ||||||
  ≥ 2.5 (ref. <2.5) | 15.7 | 4.47–99.1 | <0.0001 | 12.8 | 2.81–93.0 | 0.0006 |
Fibrosis stage | ||||||
 F3 (ref. F0-2) | 13.9 | 5.42–40.26 | <0.0001 | 8.85 | 2.99–29.3 | <0.0001 |
Activity grade | ||||||
 A2-3 (ref. A0-1) | 1.60 | 0.63–4.56 | 0.33 |  |  |  |
Treatment outcome | ||||||
 Non-SVR (ref. SVR) | 5.23 | 1.74–22.55 | 0.0020 |  |  | NS |